Thrombocytopenia - Pipeline Review, H2 2015 Is Released Thrombocytopenia - Pipeline Review, H2 2015 Summary Global Markets Direct s, Thrombocytopenia Pipeline Review, H2 2015, provides an overview of the Thrombocytopenia s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Thrombocytopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Thrombocytopenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Thrombocytopenia pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Thrombocytopenia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Thrombocytopenia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most 1
attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=167709/thrombocytopenia-pipeline-insights-2016 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=167709/thrombocytopenia-pipeline-insights-2016 Table of Contents Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Thrombocytopenia Overview 11 Therapeutics Development 12 Pipeline Products for Thrombocytopenia - Overview 12 Pipeline Products for Thrombocytopenia - Comparative Analysis 13 Thrombocytopenia - Therapeutics under Development by Companies 14 Thrombocytopenia - Therapeutics under Investigation by Universities/Institutes 16 Thrombocytopenia - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Thrombocytopenia - Products under Development by Companies 20 Thrombocytopenia - Products under Investigation by Universities/Institutes 23 Thrombocytopenia - Companies Involved in Therapeutics Development 24
2
3SBio Inc. 24 Amarillo Biosciences, Inc. 25 Amgen Inc. 26 Arcturus Therapeutics, Inc 27 aTyr Pharma, Inc. 28 Baxalta Incorporated 29 Bayer AG 30 BioLineRx, Ltd. 31 Boehringer Ingelheim GmbH 32 Bolder Biotechnology, Inc. 33 Bristol-Myers Squibb Company 34 Cellerant Therapeutics, Inc. 35 Eisai Co., Ltd. 36 Hansa Medical AB 37 Immunomedics, Inc. 38 Intas Pharmaceuticals Ltd. 39 Jiangsu Hengrui Medicine Co., Ltd. 40 Merck & Co., Inc. 41 Momenta Pharmaceuticals, Inc. 42 Myelo Therapeutics GmbH 43 Neumedicines Inc. 44 Novartis AG 45 Pfizer Inc. 46 PhytoHealth Corporation 47 3
Prophylix Pharma AS 48 Protalex, Inc. 49 Rigel Pharmaceuticals, Inc. 50 Shionogi & Co., Ltd. 51 STATegics, Inc. 52 ViroMed Co., Ltd. 53 Thrombocytopenia - Therapeutics Assessment 54 Assessment by Monotherapy Products 54 Assessment by Target 55 Assessment by Mechanism of Action 57 Assessment by Route of Administration 59 Assessment by Molecule Type 61 Drug Profiles 63 Antibody for Autoimmune Disorders and Inflammation - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 avatrombopag - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 BBT-059 - Drug Profile 66 Product Description 66 4
Mechanism of Action 66 R&D Progress 66 BI-655064 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 BL-8040 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 BMS-986004 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 CLT-009 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 eltrombopag olamine - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 eltrombopag olamine - Drug Profile 75 Product Description 75 5
Mechanism of Action 75 R&D Progress 75 fostamatinib disodium - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 GL-2045 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 GSK-2285921 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Hetrombopag Olamine - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 interferon alfa - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 LUNAR-TPO - Drug Profile 85 6
Product Description 85 Mechanism of Action 85 R&D Progress 85 lusutrombopag - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 MK-8723 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Monoclonal Antibody to Agonize TpoR for Thrombocytopenia - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 7
Myelo-001 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 NMIL-121 - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Oligonucleotides to Activate miRNA-150 for Thrombocytopenia - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 PBF-1509 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 PEG-VM501 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 PHN-013 - Drug Profile 98 Product Description 98 Mechanism of Action 98 8
R&D Progress 98 PRTX-100 - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 rivaroxaban - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 romiplostim - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 romiplostim biosimilar - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 SM-101 - Drug Profile 111 Product Description 111 Mechanism of Action 111 9
R&D Progress 111 Small Molecules to Inhibit BLVRB for Thrombocytopenia - Drug Profile 114 Product Description 114 Mechanism of Action 114 R&D Progress 114 Small Molecules to Inhibit PF4 for HIT - Drug Profile 115 Product Description 115 Mechanism of Action 115 R&D Progress 115 STST-4 - Drug Profile 116 Product Description 116 Mechanism of Action 116 R&D Progress 116 Tmax - Drug Profile 117 Product Description 117 Mechanism of Action 117 R&D Progress 117 Tromplate - Drug Profile 118 Product Description 118 Mechanism of Action 118 R&D Progress 118 TXA-302 - Drug Profile 119 Product Description 119 10
Mechanism of Action 119 R&D Progress 119 veltuzumab - Drug Profile 121 Product Description 121 Mechanism of Action 121 Read More http://www.idatainsights.com/reports-landing-page.php?id=167709/thrombocytopeniapipeline-insights-2016 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.
11